In direct compression of lyophilised Lactobacillus acidophilus pharma-grade powder, the formulation must reconcile two opposing constraints: the mechanical requirement for tablet hardness and the biological sensitivity of the vegetative cell to compressive shear and moisture. A manufacturable API lot for this route exhibits a microbial count of ≥1×10¹⁰ CFU/g, a loss on drying by Ph. Eur. 2.2.32 of ≤5.0% w/w, and a water activity by USP <922> of ≤0.25 a_w. The direct compression frame typically contains 10–30% w/w API, 45–65% w/w microcrystalline cellulose or mannitol as a low-water-activity diluent, 3–6% w/w croscarmellose sodium as disintegrant, 0.5–1.0% w/w magnesium stearate as lubricant, and 1–2% w/w colloidal silicon dioxide as glidant and desiccant. All excipients are pre-dried at 40°C for 2–4 h when ambient relative humidity exceeds 60% RH. Mixing is conducted in a low-shear tumble blender at 25 rpm for 15 min, with magnesium stearate added for the final 3 min to limit shear-induced viability loss. Compression on a rotary tablet press with 10–16 stations is maintained at 5–10 kN main compression force and 2–4 kN precompression force; higher forces produce hardness gain but cause a reproducible log-reduction in viable cells. Terminal tablets are controlled to hardness 40–70 N, friability ≤1.0% by Ph. Eur. 2.9.7, and disintegration ≤30 min by Ph. Eur. 2.9.1. Uniformity of dosage units is assessed by Ph. Eur. 2.9.40, and microbial quality is confirmed by Ph. Eur. 2.6.12/2.6.13 or USP <2021>/<2022>. The production environment is held below 30% RH and 20°C to avoid moisture migration from the air into the hygroscopic lyophilisate, and batch records are maintained under 21 CFR 210 and 211. Published data for this specific direct compression configuration is limited; therefore process qualification batches are required to correlate compression force and viability loss before commercial pack release.

Why Does Headspace Moisture Control Govern HPMC Capsule Filling of Lyophilised L. acidophilus?

Capsule filling of Lactobacillus acidophilus pharma-grade powder is governed by the water-exchange equilibrium between the shell, the fill, and the headspace. HPMC and pullulan shells contain bound moisture at 4–8% w/w; if the encapsulated powder has a water activity above 0.30 a_w, moisture migrates into the shell during storage, causing shell softening, embrittlement, and accelerated cell death. A representative fill formulation contains 15–35% w/w API, 35–55% w/w mannitol, 3–6% w/w crospovidone as disintegrant, 0.5–1.0% w/w magnesium stearate as lubricant, and 2–5% w/w sodium starch glycolate when rapid disintegration is required. The powder is filled on a dosator or dosing-disc capsule machine at 30,000–50,000 capsules/h; tamping force is kept below the threshold that compacts the powder into a plug, usually 40–80 N on the dosator pin. Fill weight for size 2 capsules is 250–400 mg, with a target fill-weight relative standard deviation ≤2.0%. Desiccant canisters containing silica gel or molecular sieve are added to HDPE bottles or aluminium blisters to keep headspace relative humidity below 20% RH. For acid-sensitive L. acidophilus strains that must bypass gastric acid, the filled HPMC capsule may be band-sealed and coated with Eudragit L 30 D-55 aqueous dispersion at a polymer weight gain of 5–8% w/w; the coating process is run in a side-vented pan at inlet air 45–55°C and product temperature 30–35°C, and the coating layer is cured at 40°C for 1 h before moisture barrier packaging. Disintegration testing per USP <701> is supplemented by two-stage dissolution in 0.1 N HCl for 2 h and pH 6.8 phosphate buffer to verify enteric protection when applicable. Microbial enumeration follows USP <2021>, and absence of specified microorganisms follows USP <2022>. The terminal product is released only after confirming that the capsule shell remains intact at 25°C and 60% RH for 3 months in accelerated stability, because shell failure is the primary cause of batch rejection on commercial lines.

For a sachet presentation intended for direct oral intake or reconstitution in water, Lactobacillus acidophilus API is granulated onto a soluble carrier to reduce dust and improve dose uniformity. A sachet formulation typically comprises 15–30% w/w API, 45–65% w/w maltodextrin or isomalt, 5–10% w/w pregelatinised starch as binder and matrix former, 2–4% w/w povidone K30, and 0.5–1.0% w/w citric acid to depress the local pH only when a strain-specific acid-resistance profile allows. The granulation is performed in a top-spray fluid-bed dryer, such as a laboratory Glatt GPCG 3 or equivalent, with inlet air at 40–50°C, product bed temperature 28–32°C, atomising air pressure 1.0–1.8 bar, and spray rate 20–40 g/min for a 5 kg batch. The dried granule is passed through a 850 µm sieve and collected above 150 µm to remove oversized agglomerates and fine API-rich dust. Residual moisture is controlled at ≤5.0% w/w by Ph. Eur. 2.2.32, and water activity is held at ≤0.25 a_w because the sachet is exposed to ambient humidity during stick-fill operations. Fill weight per sachet is typically 1.0–2.0 g, and the fill machine must be fitted with a low-humidity enclosure below 30% RH to prevent static build-up and clumping. Terminal sachets are sealed in multilaminated aluminium foil, PET, and polyethylene; the nitrogen-flushed headspace oxygen content is kept below 3% v/v. Viable count per sachet is confirmed at 1×10⁹–1×10¹⁰ CFU per dose using Ph. Eur. 2.6.12 or USP <2021>. Stability protocols follow ICH Q1A(R2) for zones I and II; real-time viability monitoring during the first commercial batches is used to set batch-specific release limits because published data for this specific fluid-bed configuration is limited.

Fluid-bed bottom-spray coating converts Lactobacillus acidophilus-containing cores into pH-responsive multiparticulates for capsule or sachet filling, allowing the organism to pass through the gastric environment before release in the intestines. The core is prepared either by extrusion-spheronization or by layering the API onto microcrystalline cellulose spheres; a representative core contains 20–35% w/w API, 30–50% w/w microcrystalline cellulose, 10–20% w/w mannitol or lactose, and 2–5% w/w hypromellose as binder. The enteric coating is prepared from Eudragit L 30 D-55 aqueous dispersion, with triethyl citrate at 10–20% w/w of dry polymer as plasticiser and talc at 25–50% w/w of dry polymer as anti-tack agent; the target dry polymer weight gain is 12–18% w/w. Coating is carried out in a Wurster HS insert fitted to a fluid-bed processor, with inlet air at 45–55°C, product bed temperature 28–32°C, and spray rate 8–15 g/min for a 1 kg core batch. After coating, the pellets are cured at 40°C for 1 h, then blended with 1–2% w/w colloidal silicon dioxide before encapsulation. The terminal product is tested by a two-stage compendial procedure: after 2 h in 0.1 N HCl, less than 10% of the labelled viable count is released; after transfer to pH 6.8 phosphate buffer, release is ≥80% within 45 min under USP <711> or Ph. Eur. 2.9.3. Because the coating dispersion is aqueous, the core moisture must be below 5.0% w/w before coating and the product temperature must remain below 32°C to avoid thermal death of the vegetative strain. Viable count and specified-organism testing follow USP <2021> and USP <2022>, with a release count of ≥1×10¹⁰ CFU/g at the pellet level. Production-scale processors show batch-to-batch variability in coating thickness at the bottom of the Wurster column, so coating efficiency and agglomeration are monitored via laser diffraction after each coating cycle.

When a Non-Aqueous Oral Suspension Is Required for Enteral or Paediatric Dosing

Lactobacillus acidophilus displays poor aqueous stability at ambient temperature, so a ready-to-use oral liquid for paediatric or enteral administration is formulated as a non-aqueous suspension rather than a solution. The vehicle is typically medium-chain triglycerides, refined sunflower oil, or fractionated coconut oil; the API is suspended at 5–25% w/w, with 2–4% w/w colloidal silicon dioxide or fumed silica as structuring agent, 0.3–0.8% w/w lecithin as wetting agent, and 0.01–0.05% w/w butylated hydroxytoluene as antioxidant. The suspension is prepared under low-shear mixing at 500–1000 rpm and cooled to 15–20°C; homogenisation is avoided because rotor-stator high-shear devices raise the product temperature and reduce viable count. Viscosity is adjusted to 300–1500 mPa·s to maintain dose uniformity without hindering oral syringe withdrawal. The oil vehicle gives a water activity below 0.60 a_w, which slows water-mediated degradation, but the preparation is not sterile; microbial enumeration by USP <2021> and specified-organism testing by USP <2022> are release tests. Terminal bottles are filled under nitrogen and sealed with child-resistant closures; the fill volume is typically 30–100 mL with a liquid headspace oxygen content below 5% v/v. Before administration, the labelled instructions state that the suspension should not be mixed with acidic fruit juice or warm water because the resulting pH and temperature shift can reduce viability within 15 min. Published data for long-term viability in non-aqueous probiotic suspensions is limited; therefore real-time stability at 2–8°C is used to establish shelf life, and a label condition of 2–8°C storage is applied unless accelerated data support a higher storage temperature.

Freeze-dried orodispersible tablets containing Lactobacillus acidophilus combine the low-moisture stabilisation of the API with rapid disintegration in the oral cavity. The unit-dose matrix is formed by suspending 10–20% w/w API in an aqueous solution containing 40–60% w/w mannitol as structural bulking agent, 2–5% w/w gelatin or fish gelatin as binder, 1–3% w/w pullulan as matrix modifier, and a pH-neutral buffer to avoid osmotic shock to the bacterial cell during freezing. The suspension is dosed into preformed aluminium/PVC blisters at 0.5–1.0 mL per unit, then frozen to -40°C at a cooling rate of 1°C/min. Primary drying is performed on a lyophiliser with shelf temperature -20°C to -10°C and chamber pressure 50–150 µbar; secondary drying at 20–30°C reduces moisture to ≤2.0% w/w. The terminal wafer has a disintegration time of ≤10 seconds under Ph. Eur. 2.9.1 and a water activity below 0.25 a_w. Because the matrix is highly hygroscopic, the blisters are sealed with peel-off aluminium lidding under nitrogen at ≤3% v/v oxygen headspace. Viable count after freeze drying is confirmed at 1×10⁹–1×10¹⁰ CFU per unit using USP <2021>; uniformity of dosage units is evaluated by Ph. Eur. 2.9.40. Scale-up from laboratory trays to production lyophilisers introduces batch-to-batch variation in freezing rate and cake collapse; therefore thermal mapping and sublimation rate data are collected for each shelf during process qualification. The main limitation of this presentation is mechanical fragility: cracked cakes are rejected because oxygen and moisture ingress reduce cell survival and appearance.

Aseptic Lyophilised Vial Presentation and Endotoxin Barriers for Parenteral L. acidophilus Fractions

For injectable requests, the viable whole-cell route lacks a recognised monograph in the USP, Ph. Eur., or JP for parenteral use, and published data for a licensed live Lactobacillus acidophilus injection is limited. Injectable development is therefore restricted to inactivated whole-cell fractions, lysates, or cell-wall preparations, not to live probiotics. The API is washed by tangential flow filtration, heat-inactivated at 70–80°C for 30–60 min when a non-viable fraction is intended, and resuspended in a cryoprotectant solution containing 5–10% w/v sucrose, 5–10% w/v trehalose, and 2–5% w/v mannitol. The suspension is aseptically filled into depyrogenated Type I glass vials in an ISO 14644-1 Class 5 cleanroom; sterile filtration of intact bacterial cells is not feasible, so aseptic processing replaces terminal filtration. If the fraction is inactivated, terminal moist-heat sterilisation at 121°C for 15 min may be applied, but this cannot be used for live-cell products because the vegetative organism is killed. Lyophilisation is run with primary drying at shelf temperature -25°C to -10°C and chamber pressure 50–150 µbar, followed by secondary drying at 20–30°C for 16–24 h; the final cake moisture is ≤1.0% w/w. Sterility testing follows USP <71> or Ph. Eur. 2.6.1 on both the bulk suspension and the finished vial. Bacterial endotoxin content of the reconstituted solution is determined by USP <85> or Ph. Eur. 2.6.14, with the limit calculated from the intended dose; the water for injection used for reconstitution must meet an endotoxin specification of ≤0.25 EU/mL. Phosphate-buffered cryoprotectants are avoided when calcium chloride is present because insoluble calcium phosphate can precipitate during freezing and clog the filling line. The terminal presentation is a sealed single-dose vial with an inert nitrogen headspace and a label that states the preparation is for investigational use only; intravenous, intramuscular, or subcutaneous administration of live L. acidophilus is not supported by compendial standards.